Study shows similar outcomes with RIC and MAC in MDS



HSCT preparation
Photo by Chad McNeeley
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat myelodysplastic syndromes (MDS), regardless of the conditioning regimen they received. Rates of engraftment, graft-vs-host disease (GVHD), relapse, and survival were similar between patients who received reduced-intensity... [Read Article]

Combo improves response rates in treatment-naïve SAA



Eltrombopag (Promacta)
Photo courtesy of GSK
Adding eltrombopag to immunosuppressive therapy (IST) can produce high rates of response in treatment-naïve severe aplastic anemia (SAA), according to research published in NEJM. In patients who received eltrombopag for 6 months, the overall response rate (ORR) was 94%, and the complete response (CR) rate was 58%.... [Read Article]